Trendy anti-aging biotech Unity adds $55M as it preps first human trial to flush senescent cells
Unity Biotechnology is filling up its cash reserves with another venture round before it goes into its first anti-aging human studies.
The Bay Area biotech bagged a $116 million celebrity round in 2016, with Jeff Bezos and others joining the syndicate for the Arch-seeded company, launched with Bob Nelsen’s help. That followed an $11 million seed round and a $35 million extension on the B. And now it’s settling for a relatively modest $55 million for the C round, bringing the total to 217 million so far for the preclinical company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
